The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs.
antibodies
dependovirus
genetic therapy
neutralizing
treatment outcome
virus vector
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
08 Dec 2022
08 Dec 2022
Historique:
received:
21
06
2022
accepted:
24
10
2022
entrez:
16
11
2022
pubmed:
17
11
2022
medline:
17
11
2022
Statut:
epublish
Résumé
Adeno-associated virus (AAV) vectors are promising modalities of gene therapy to address unmet medical needs. However, anti-AAV neutralizing antibodies (NAbs) hamper the vector-mediated therapeutic effect. Therefore, NAb prevalence in the target population is vital in designing clinical trials with AAV vectors. Hence, updating the seroprevalence of anti-AAV NAbs, herein we analyzed sera from 100 healthy individuals and 216 hemophiliacs in Japan. In both groups, the overall seroprevalence against various AAV serotypes was 20%-30%, and the ratio of the NAb-positive population increased with age. The seroprevalence did not differ between healthy participants and hemophiliacs and was not biased by the concomitant blood-borne viral infections. The high neutralizing activity, which strongly inhibits the transduction with all serotypes
Identifiants
pubmed: 36381300
doi: 10.1016/j.omtm.2022.10.014
pii: S2329-0501(22)00156-5
pmc: PMC9661668
doi:
Types de publication
Journal Article
Langues
eng
Pagination
404-414Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
All authors have no competing financial interests to declare.
Références
J Virol. 1999 Oct;73(10):8549-58
pubmed: 10482608
Hum Gene Ther. 2010 Jun;21(6):704-12
pubmed: 20095819
Mol Ther. 2017 Aug 2;25(8):1831-1842
pubmed: 28596114
J Virol. 2005 Dec;79(23):14781-92
pubmed: 16282478
Hum Gene Ther. 2022 Apr;33(7-8):442-450
pubmed: 34861783
Mol Ther Methods Clin Dev. 2021 Jun 12;22:162-171
pubmed: 34485602
Hum Gene Ther. 2022 Apr;33(7-8):432-441
pubmed: 35156839
Gene Ther. 2014 Aug;21(8):732-8
pubmed: 24849042
Gene Ther. 2016 Mar;23(3):313-9
pubmed: 26699914
JAMA. 2021 May 11;325(18):1896-1898
pubmed: 33739374
Mol Ther Methods Clin Dev. 2019 May 28;14:27-36
pubmed: 31276009
Sci Transl Med. 2013 Jul 17;5(194):194ra92
pubmed: 23863832
Nat Protoc. 2006;1(3):1412-28
pubmed: 17406430
Hum Gene Ther. 2006 Apr;17(4):440-7
pubmed: 16610931
J Infect Dis. 2009 Feb 1;199(3):381-90
pubmed: 19133809
Hum Gene Ther. 2019 Oct;30(10):1297-1305
pubmed: 31502485
FEBS Lett. 2019 Dec;593(24):3571-3582
pubmed: 31411731
Blood. 2022 Apr 11;:
pubmed: 35405003
Nat Commun. 2018 Oct 5;9(1):4098
pubmed: 30291246
Science. 2018 Jan 12;359(6372):
pubmed: 29326244
J Virol. 2004 Aug;78(15):7874-82
pubmed: 15254160
J Med Virol. 2014 Nov;86(11):1990-7
pubmed: 24136735
Gene Ther. 2012 Mar;19(3):288-94
pubmed: 21697954
Hum Gene Ther. 2021 May;32(9-10):451-457
pubmed: 33207962
Mol Ther. 2020 Sep 2;28(9):2073-2082
pubmed: 32559433
Res Pract Thromb Haemost. 2019 Jan 25;3(2):261-267
pubmed: 31011710
Transl Vis Sci Technol. 2019 Apr 09;8(2):14
pubmed: 31016068
Gene Ther. 2019 Jun;26(6):250-263
pubmed: 30962537
Haemophilia. 2021 Feb;27 Suppl 3:132-141
pubmed: 32638467
Hum Gene Ther. 2019 Jan;30(1):79-87
pubmed: 30027761
Mol Ther Methods Clin Dev. 2019 Jun 07;14:126-133
pubmed: 31338384
Cell Immunol. 2019 Aug;342:103780
pubmed: 29571923
Mol Ther. 2013 Feb;21(2):318-23
pubmed: 23247100
Mol Ther. 2011 Nov;19(11):2084-91
pubmed: 21629225
N Engl J Med. 2014 Nov 20;371(21):1994-2004
pubmed: 25409372
Microbiol Immunol. 2007;51(2):185-91
pubmed: 17310086
Nat Med. 2006 Mar;12(3):342-7
pubmed: 16474400
Vox Sang. 1998;74(4):225-7
pubmed: 9691402
Hum Gene Ther Clin Dev. 2016 Jun;27(2):79-82
pubmed: 27314914